Drug approval in Switzerland much slower than in Europe
Published: Wednesday, Jul 24th 2024, 15:50
Back to Live Feed
According to a new study, medicines are approved on average 249 days later in Switzerland than at the European Medicines Agency (EMA). According to Interpharma, this means that access to vital medicines is becoming increasingly difficult.
The benchmarking study carried out by the pharmaceutical industry and Swissmedic shows that companies in Switzerland are submitting their applications later than in Europe and that the time taken to review them has also increased, Interpharma, the association of research-based pharmaceutical companies, announced on Wednesday.
On average, a drug is approved in Switzerland 249 days later than at the EMA. This represents an increase of 48 percent compared to the previous year. Companies submitted their authorization applications to Swissmedic 244 days later than to the EMA.
Interpharma sees the poor framework conditions in Switzerland as the reason for this: these have led to the Swiss market having less and less priority.
©Keystone/SDA
English 
German 
French 
Spanish 
Arabic